arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TScan Therapeutics, Inc.

TCRX
$0.36 ▲ +0.01 (+3.58%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

TScan Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $46.8M
Dividend Yield
Revenue Growth -65.8%
Op. Margin None
ROIC -23.7%
FCF / Share $-0.22
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity 0.47
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.05M
↓ -65.8%
Net Income Profit after all expenses
$-30.36M
↑ +17.8%
Operating Margin Operating profit as % of sales
-296.2%
↑ +11.4%
FCF / Share Free cash flow per share
$-0.22
↑ +19.0%
Long-Term Debt Long-term obligations
$32.78M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
8
Financial Health
42
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters